<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625283</url>
  </required_header>
  <id_info>
    <org_study_id>200210</org_study_id>
    <nct_id>NCT04625283</nct_id>
  </id_info>
  <brief_title>The Impact of Perioperative Ketamine Infusion on Surgical Recovery</brief_title>
  <official_title>The Effect and Contribution of a Perioperative Ketamine Infusion in an Established Enhanced Recovery Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to effectively treat surgical pain with the least amount of opioids required, a&#xD;
      multi-modal approach must include medications with different mechanisms of actions at&#xD;
      alternative receptors. In light of the opioid epidemic, medical providers at Vanderbilt&#xD;
      University Medical Center (VUMC) are strategically combining these medications in a bundled&#xD;
      pain-regimen after surgery. These regimens have been shown to decrease opioid consumption,&#xD;
      improve surgical outcomes, and reduce hospital stays, thus coining the term 'enhanced&#xD;
      recovery pathway'. The combination of these medications has an indisputable synergistic&#xD;
      effect. However, it is unknown how each medication contributes individually to the overall&#xD;
      efficacy of the pathway. This study will examine the effects of ketamine, within the&#xD;
      constructs of a multimodal pain regimen, on a) length of stay, b) opioid consumption, c) pain&#xD;
      scores, and d) surgical outcomes after major abdominal surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opioids are powerful analgesic medications that can reduce pain through action at the mu&#xD;
      receptor. Unfortunately, activation of the mu receptor also results in undesirable side&#xD;
      effects, such as respiratory depression, sedation, bowel ileus, nausea, itching, and&#xD;
      tolerance. Therefore, in order to effectively treat pain with the least amount of opioids&#xD;
      required, a multi-modal approach must include medications with different mechanisms of&#xD;
      actions at alternative receptors. Some examples of non-narcotic pain medications include&#xD;
      acetaminophen (Tylenol), anti-inflammatories (NSAIDS), muscle relaxants, local anesthetics,&#xD;
      gabapentinoids (Lyrica), and ketamine, to name a few. In light of the opioid epidemic,&#xD;
      medical providers at Vanderbilt University Medical Center (VUMC) are strategically combining&#xD;
      these medications in a bundled pain-regimen after surgery. These regimens have been shown to&#xD;
      decrease opioid consumption, improve surgical outcomes, and reduce hospital stays, thus&#xD;
      coining the term 'enhanced recovery pathway' or enhanced recovery after surgery (ERAS). The&#xD;
      combination of these medications has an indisputable synergistic effect. However, it is&#xD;
      unknown how each medication contributes individually to the overall efficacy of the pathway.&#xD;
      Ultimately, the investigators aim to perform a series of randomized controlled trials in&#xD;
      which we isolate each component of the pathway to investigate its effects on length of stay,&#xD;
      total opioid consumption, pain scores, and surgical outcomes. The investigators will begin&#xD;
      with studying ketamine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be performed as a pragmatic controlled clinical trial with parallel group assignment. Randomization will be in a cluster format.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>From hospital admission until discharge, typically 3-5 days</time_frame>
    <description>The participants total hospital length of stay measured in days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total consumption of inpatient opioids</measure>
    <time_frame>From hospital admission until discharge, typically 3-5 days</time_frame>
    <description>Inpatient opioid consumption measured in morphine milligram equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>Inpatient baseline day through inpatient day 3</time_frame>
    <description>Numerical pain scores, ranging from 0 to 10 with 0 being no pain and 10 being worse pain possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Surgical Outcomes - Return of bowel function</measure>
    <time_frame>From hospital admission until discharge, typically 3-5 days</time_frame>
    <description>Return of bowel function measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Surgical Outcomes - Gastrointestinal Complications</measure>
    <time_frame>From hospital admission until discharge, typically 3-5 days</time_frame>
    <description>Incidence of ileus and/or nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Surgical Outcomes - Rapid Response</measure>
    <time_frame>From hospital admission until discharge, typically 3-5 days</time_frame>
    <description>Rapid response as a binary outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Surgical Outcomes - ICU Transfer</measure>
    <time_frame>From hospital admission until discharge, typically 3-5 days</time_frame>
    <description>Transfer to ICU as a binary outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Side Effects</measure>
    <time_frame>From hospital admission until discharge, typically 3-5 days</time_frame>
    <description>Total incidence of side effects (hallucination, sedation, lightheadedness, patient request) as adverse reactions requiring early cessation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Opioid Use</condition>
  <condition>Enhanced Recovery After Surgery</condition>
  <condition>Anesthesia</condition>
  <condition>Ketamine</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive intraoperative ketamine bolus (0.5mg/kg) followed by continuous infusion 5 mcg/kg/min and also will receive postoperative ketamine infusion (2.5 mg/kg/min, up to 100kg max) for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive an equivalent volume of intraoperative saline bolus followed by continuous saline infusion and also will receive postoperative saline infusion for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Participants in the ketamine arm will receive intraoperative and postoperative ketamine.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in the placebo arm will receive intraoperative and postoperative saline.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old or greater&#xD;
&#xD;
          -  presenting at VUMC for abdominal surgery on the colorectal, ventral hernia or surgical&#xD;
             oncology services on a weekday.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy or contraindication to ketamine&#xD;
&#xD;
          -  unable or refuse to receive a regional nerve block&#xD;
&#xD;
          -  patient refusal&#xD;
&#xD;
          -  direct transfer from operating room to intensive care unit with endotracheal tube&#xD;
             placed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britany L Raymond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boenigk K, Echevarria GC, Nisimov E, von Bergen Granell AE, Cuff GE, Wang J, Atchabahian A. Low-dose ketamine infusion reduces postoperative hydromorphone requirements in opioid-tolerant patients following spinal fusion: A randomised controlled trial. Eur J Anaesthesiol. 2019 Jan;36(1):8-15. doi: 10.1097/EJA.0000000000000877.</citation>
    <PMID>30113350</PMID>
  </reference>
  <reference>
    <citation>Kaur S, Saroa R, Aggarwal S. Effect of intraoperative infusion of low-dose ketamine on management of postoperative analgesia. J Nat Sci Biol Med. 2015 Jul-Dec;6(2):378-82. doi: 10.4103/0976-9668.160012.</citation>
    <PMID>26283834</PMID>
  </reference>
  <reference>
    <citation>Kim SH, Kim SI, Ok SY, Park SY, Kim MG, Lee SJ, Noh JI, Chun HR, Suh H. Opioid sparing effect of low dose ketamine in patients with intravenous patient-controlled analgesia using fentanyl after lumbar spinal fusion surgery. Korean J Anesthesiol. 2013 Jun;64(6):524-8. doi: 10.4097/kjae.2013.64.6.524. Epub 2013 Jun 24.</citation>
    <PMID>23814653</PMID>
  </reference>
  <reference>
    <citation>Suppa E, Valente A, Catarci S, Zanfini BA, Draisci G. A study of low-dose S-ketamine infusion as &quot;preventive&quot; pain treatment for cesarean section with spinal anesthesia: benefits and side effects. Minerva Anestesiol. 2012 Jul;78(7):774-81. Epub 2012 Feb 29.</citation>
    <PMID>22374377</PMID>
  </reference>
  <reference>
    <citation>Remérand F, Le Tendre C, Baud A, Couvret C, Pourrat X, Favard L, Laffon M, Fusciardi J. The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study. Anesth Analg. 2009 Dec;109(6):1963-71. doi: 10.1213/ANE.0b013e3181bdc8a0.</citation>
    <PMID>19923527</PMID>
  </reference>
  <reference>
    <citation>Pergolizzi JV Jr, Rosenblatt M, LeQuang JA. Three Years Down the Road: The Aftermath of the CDC Guideline for Prescribing Opioids for Chronic Pain. Adv Ther. 2019 Jun;36(6):1235-1240. doi: 10.1007/s12325-019-00954-1. Epub 2019 Apr 23.</citation>
    <PMID>31016474</PMID>
  </reference>
  <reference>
    <citation>Kent ML, Hurley RW, Oderda GM, Gordon DB, Sun E, Mythen M, Miller TE, Shaw AD, Gan TJ, Thacker JKM, McEvoy MD; POQI-4 Working Group. American Society for Enhanced Recovery and Perioperative Quality Initiative-4 Joint Consensus Statement on Persistent Postoperative Opioid Use: Definition, Incidence, Risk Factors, and Health Care System Initiatives. Anesth Analg. 2019 Aug;129(2):543-552. doi: 10.1213/ANE.0000000000003941.</citation>
    <PMID>30897590</PMID>
  </reference>
  <reference>
    <citation>Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, Bohnert ASB, Kheterpal S, Nallamothu BK. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017 Jun 21;152(6):e170504. doi: 10.1001/jamasurg.2017.0504. Epub 2017 Jun 21. Erratum in: JAMA Surg. 2019 Mar 1;154(3):272.</citation>
    <PMID>28403427</PMID>
  </reference>
  <reference>
    <citation>Kurokawa Y, Kurokawa T, Tanimoto T. Opioid Prescription After Surgery. JAMA Surg. 2019 Jul 1;154(7):675. doi: 10.1001/jamasurg.2019.0573.</citation>
    <PMID>31017640</PMID>
  </reference>
  <reference>
    <citation>Mercadante S. Opioid Analgesics Adverse Effects: The Other Side of the Coin. Curr Pharm Des. 2019;25(30):3197-3202. doi: 10.2174/1381612825666190717152226. Review.</citation>
    <PMID>31333113</PMID>
  </reference>
  <reference>
    <citation>McEvoy MD, Wanderer JP, King AB, Geiger TM, Tiwari V, Terekhov M, Ehrenfeld JM, Furman WR, Lee LA, Sandberg WS. A perioperative consult service results in reduction in cost and length of stay for colorectal surgical patients: evidence from a healthcare redesign project. Perioper Med (Lond). 2016 Feb 5;5:3. doi: 10.1186/s13741-016-0028-1. eCollection 2016.</citation>
    <PMID>26855773</PMID>
  </reference>
  <reference>
    <citation>Hawkins AT, Geiger TM, King AB, Wanderer JP, Tiwari V, Muldoon RL, Ford MM, Dmochowski RR, Sandberg WS, Martin B, Hopkins MB, McEvoy MD. An enhanced recovery program in colorectal surgery is associated with decreased organ level rates of complications: a difference-in-differences analysis. Surg Endosc. 2019 Jul;33(7):2222-2230. doi: 10.1007/s00464-018-6508-2. Epub 2018 Oct 17.</citation>
    <PMID>30334161</PMID>
  </reference>
  <reference>
    <citation>King AB, Spann MD, Jablonski P, Wanderer JP, Sandberg WS, McEvoy MD. An enhanced recovery program for bariatric surgical patients significantly reduces perioperative opioid consumption and postoperative nausea. Surg Obes Relat Dis. 2018 Jun;14(6):849-856. doi: 10.1016/j.soard.2018.02.010. Epub 2018 Feb 13.</citation>
    <PMID>29555468</PMID>
  </reference>
  <reference>
    <citation>Li Z, Zhao Q, Bai B, Ji G, Liu Y. Enhanced Recovery After Surgery Programs for Laparoscopic Abdominal Surgery: A Systematic Review and Meta-analysis. World J Surg. 2018 Nov;42(11):3463-3473. doi: 10.1007/s00268-018-4656-0.</citation>
    <PMID>29750324</PMID>
  </reference>
  <reference>
    <citation>Greco M, Capretti G, Beretta L, Gemma M, Pecorelli N, Braga M. Enhanced recovery program in colorectal surgery: a meta-analysis of randomized controlled trials. World J Surg. 2014 Jun;38(6):1531-41. doi: 10.1007/s00268-013-2416-8. Review.</citation>
    <PMID>24368573</PMID>
  </reference>
  <reference>
    <citation>Doan LV, Wang J. An Update on the Basic and Clinical Science of Ketamine Analgesia. Clin J Pain. 2018 Nov;34(11):1077-1088. doi: 10.1097/AJP.0000000000000635. Review.</citation>
    <PMID>29927768</PMID>
  </reference>
  <reference>
    <citation>Brinck EC, Tiippana E, Heesen M, Bell RF, Straube S, Moore RA, Kontinen V. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database Syst Rev. 2018 Dec 20;12:CD012033. doi: 10.1002/14651858.CD012033.pub4.</citation>
    <PMID>30570761</PMID>
  </reference>
  <reference>
    <citation>Peyton PJ, Wu C, Jacobson T, Hogg M, Zia F, Leslie K. The effect of a perioperative ketamine infusion on the incidence of chronic postsurgical pain-a pilot study. Anaesth Intensive Care. 2017 Jul;45(4):459-465.</citation>
    <PMID>28673215</PMID>
  </reference>
  <reference>
    <citation>Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, Bhatia A, Davis FN, Hooten WM, Cohen SP. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018 Jul;43(5):456-466. doi: 10.1097/AAP.0000000000000806.</citation>
    <PMID>29870457</PMID>
  </reference>
  <reference>
    <citation>Allen CA, Ivester JR Jr. Low-Dose Ketamine for Postoperative Pain Management. J Perianesth Nurs. 2018 Aug;33(4):389-398. doi: 10.1016/j.jopan.2016.12.009. Epub 2017 Jun 10.</citation>
    <PMID>30077280</PMID>
  </reference>
  <reference>
    <citation>Plyler SS, Muckler VC, Titch JF, Gupta DK, Rice AN. Low-Dose Ketamine Infusion to Decrease Postoperative Delirium for Spinal Fusion Patients. J Perianesth Nurs. 2019 Aug;34(4):779-788. doi: 10.1016/j.jopan.2018.11.009. Epub 2019 Feb 10.</citation>
    <PMID>30745263</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Britany Lynn Raymond, MD</investigator_full_name>
    <investigator_title>MD, Assistant Professor, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>ERAS</keyword>
  <keyword>Enhanced Recovery After Surgery</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Opioid</keyword>
  <keyword>Learning Healthcare System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators do not plan to share individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

